| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Wolfgang Jelkmann | Q114451997 |
| P2860 | cites work | Efficiency of signalling through cytokine receptors depends critically on receptor orientation | Q22003959 |
| The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 | ||
| Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha | Q24291726 | ||
| C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation | Q24291783 | ||
| A conserved family of prolyl-4-hydroxylases that modify HIF | Q24291794 | ||
| FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity | Q24291819 | ||
| A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation | Q24294741 | ||
| Isolation and characterization of genomic and cDNA clones of human erythropoietin | Q24299960 | ||
| FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor | Q24300161 | ||
| Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803 | Q24306213 | ||
| Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension | Q24307473 | ||
| Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element | Q24528175 | ||
| A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis | Q24536498 | ||
| HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation | Q24555773 | ||
| Cloning and expression of the human erythropoietin gene | Q24608978 | ||
| Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway | Q24672316 | ||
| Cobalt chloride administration in athletes: a new perspective in blood doping? | Q24672328 | ||
| A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development | Q24681396 | ||
| Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A | Q27732820 | ||
| NMR structure of human erythropoietin and a comparison with its receptor bound conformation | Q27765719 | ||
| Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation | Q27766884 | ||
| Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor | Q28118068 | ||
| Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation | Q28188357 | ||
| Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch | Q28217194 | ||
| Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals | Q28236222 | ||
| JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin | Q28260976 | ||
| Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis | Q36507323 | ||
| The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. | Q36550495 | ||
| Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice | Q36622808 | ||
| Redox regulation of the hypoxia-inducible factor | Q36642721 | ||
| The human erythropoietin-encoding gene contains a CAAT box, TATA boxes and other transcriptional regulatory elements in its 5' flanking region | Q36785443 | ||
| Small peptides as potent mimetics of the protein hormone erythropoietin | Q36802815 | ||
| Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry | Q36884402 | ||
| Expression of the erythropoietin gene | Q36917476 | ||
| Anemia induces accumulation of erythropoietin mRNA in the kidney and liver | Q36918011 | ||
| Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury | Q37250532 | ||
| Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism | Q37399458 | ||
| Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro | Q37481031 | ||
| Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene | Q37541263 | ||
| Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor | Q37571920 | ||
| Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus | Q37579303 | ||
| Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice | Q37601187 | ||
| Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin | Q38294090 | ||
| Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease | Q38337379 | ||
| HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels | Q38346980 | ||
| Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. | Q38355340 | ||
| Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions | Q38360226 | ||
| Involvement of Ca2+-independent phospholipase A2 in the translocation of hypoxia-inducible factor-1alpha to the nucleus under hypoxic conditions | Q40231221 | ||
| Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). | Q40351752 | ||
| Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact | Q40411510 | ||
| Synthetic erythropoietic proteins: tuning biological performance by site-specific polymer attachment | Q40434711 | ||
| Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond | Q40436923 | ||
| Is the renal production of erythropoietin controlled by the brain stem? | Q40443345 | ||
| Myelodysplastic syndrome. | Q40452972 | ||
| Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway | Q40484626 | ||
| GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression | Q40505328 | ||
| Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. | Q40563648 | ||
| Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity | Q40612658 | ||
| The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen | Q40631949 | ||
| Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein | Q40671839 | ||
| Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys | Q40721597 | ||
| Structural analysis of sulfated N-linked oligosaccharides in erythropoietin | Q40755704 | ||
| Erythropoietin mimetics derived from solution phase combinatorial libraries | Q40755835 | ||
| Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain | Q40795310 | ||
| Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells | Q40798013 | ||
| Erythropoietin receptor expression in human melanoma cells | Q40839975 | ||
| A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation | Q40941866 | ||
| How to diagnose and correct iron deficiency during r-huEPO therapy--a consensus report | Q41009226 | ||
| Erythropoietin upregulates the expression of its own receptor in TF-1 cell line | Q41041874 | ||
| Gene transfer for erythropoiesis enhancement | Q41105474 | ||
| The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line | Q41250615 | ||
| Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein | Q41337564 | ||
| Erythropoietin therapy | Q41384536 | ||
| Retinoic acid up-regulates erythropoietin production in hepatoma cells and in vitamin A-depleted rats | Q41450278 | ||
| Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements | Q41591510 | ||
| Demonstration of high levels of erythropoietin in rat kidneys following hypoxic hypoxia | Q41640743 | ||
| The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells--signals emanating from the erythropoietin receptor | Q41659068 | ||
| Role of cytochrome P450 in the control of the production of erythropoietin | Q41752741 | ||
| Enhancement of heme and globin synthesis in cultured human marrow by certain 5 -H steroid metabolites | Q42023813 | ||
| Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells | Q42435444 | ||
| Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization | Q36458416 | ||
| Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors | Q28262857 | ||
| Normalization of hemoglobin level in patients with chronic kidney disease and anemia | Q28274269 | ||
| Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells | Q28282130 | ||
| Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 | Q28282227 | ||
| Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways | Q28287538 | ||
| Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit | Q28298336 | ||
| A developmental transition in definitive erythropoiesis: erythropoietin expression is sequentially regulated by retinoic acid receptors and HNF4 | Q28362273 | ||
| Development and characterization of novel erythropoiesis stimulating protein (NESP) | Q28362976 | ||
| Purification and characterization of hypoxia-inducible factor 1 | Q28678375 | ||
| Mitochondrial reactive oxygen species trigger hypoxia-induced transcription | Q29614203 | ||
| Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein | Q29615928 | ||
| Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes | Q29617594 | ||
| Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry | Q30404030 | ||
| New erythropoietic proteins: rationale and clinical data | Q30936857 | ||
| Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells | Q32048225 | ||
| The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif | Q32138809 | ||
| Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway | Q33180653 | ||
| Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia | Q33256941 | ||
| Recombinant human thrombopoietin: basic biology and evaluation of clinical studies | Q33345058 | ||
| La pression barométrique: Paul Bert's hypoxia theory and its critics | Q33472283 | ||
| New epoetin molecules and novel therapeutic approaches | Q33639214 | ||
| Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells | Q33730124 | ||
| Healthcare systems. An international review. Introduction | Q33755437 | ||
| Signal transduction in the erythropoietin receptor system | Q33783537 | ||
| Adaptation and conservation of physiological systems in the evolution of human hypoxia tolerance | Q33799537 | ||
| Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades | Q34086191 | ||
| Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality | Q34150075 | ||
| Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia | Q34157665 | ||
| Enhancement of therapeutic protein in vivo activities through glycoengineering | Q34180647 | ||
| Role of the kidney in erythropoiesis | Q34241097 | ||
| Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production | Q34248310 | ||
| A direct measurement of the radiation sensitivity of normal mouse bone marrow cells | Q34249472 | ||
| Carbon Monoxide: a Putative Neural Messenger | Q34305648 | ||
| Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression | Q34320660 | ||
| Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death | Q34411455 | ||
| A potential role for erythropoietin in focal permanent cerebral ischemia in mice. | Q42473313 | ||
| Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors | Q42489065 | ||
| Erythropoietin gene expression in different areas of the developing human central nervous system. | Q42498375 | ||
| Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma | Q42525531 | ||
| A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation | Q42646877 | ||
| Lack of sex dependence of the serum level of immunoreactive erythropoietin in chronic anemia | Q43476959 | ||
| Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo | Q43627722 | ||
| The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study | Q43636269 | ||
| Genetic heterogeneity of primary familial and congenital polycythemia | Q43739634 | ||
| Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy | Q44486191 | ||
| Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels | Q44534261 | ||
| Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure | Q44948985 | ||
| Human erythropoietin gene therapy for patients with chronic renal failure | Q45044565 | ||
| Progress in the purfication of erythropoietin | Q45224760 | ||
| Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumor Cell Survival | Q46044225 | ||
| Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia | Q46315752 | ||
| Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex | Q46325365 | ||
| Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa | Q46505300 | ||
| The prolonged half-lives of new erythropoietin derivatives via peptide addition | Q46824865 | ||
| Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction | Q46931184 | ||
| Derivatives of erythropoietin that are tissue protective but not erythropoietic | Q47213815 | ||
| Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway | Q47612450 | ||
| Evidence for an erythropoietin receptor protein on rat bone marrow cells | Q47869159 | ||
| Erythroid colony formation in cultures of mouse and human bone marrow: Analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A | Q47878288 | ||
| Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts | Q47951521 | ||
| The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients | Q47993808 | ||
| Immunohistochemical localization of erythropoietin and its receptor in the developing human brain | Q48289607 | ||
| Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma | Q48882565 | ||
| Erythropoietin gene expression in human, monkey and murine brain | Q49015563 | ||
| La pression barométrique : recherches de physiologie expérimentale | Q51379863 | ||
| Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. | Q51614218 | ||
| Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. | Q51639478 | ||
| Hepatic erythropoietin gene regulation by GATA-4. | Q52098524 | ||
| Where does preoperative erythropoietin therapy count? A mathematical perspective. | Q52216732 | ||
| Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. | Q53029316 | ||
| Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. | Q53399782 | ||
| Erythropoietin: a somewhat personal history. | Q53631173 | ||
| Erythropoietin regulates endothelial progenitor cells | Q53854344 | ||
| Phosphatidylserine exposure in B lymphocytes: a role for lipid packing | Q57374987 | ||
| Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization | Q58816341 | ||
| Bio-Assay of Erythropoietin in Mice Made PolycythÆmic by Exposure to Air at a Reduced Pressure | Q59092001 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. | Q34529820 | ||
| Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling | Q34960679 | ||
| Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood | Q35011782 | ||
| Functional erythropoietin autocrine loop in melanoma | Q35083677 | ||
| Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. | Q35144156 | ||
| Anemia management and the delay of chronic renal failure progression | Q35159401 | ||
| Erythropoietin receptor mRNA expression in human endothelial cells | Q35208338 | ||
| Expression cloning of the murine erythropoietin receptor | Q35416452 | ||
| The cardiovascular effects of erythropoietin | Q35538417 | ||
| EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer | Q35558558 | ||
| Epoetin alfa. Clinical evolution of a pleiotropic cytokine | Q35652564 | ||
| The molecular mechanism of erythropoietin action | Q35657845 | ||
| Role of apoptosis in reperfusion injury | Q35666886 | ||
| HIFs and tumors--causes and consequences | Q35683703 | ||
| Mimicry of erythropoietin by a nonpeptide molecule | Q35735812 | ||
| Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression | Q35791446 | ||
| Human erythropoietin dimers with markedly enhanced in vivo activity | Q35799107 | ||
| An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. | Q35833911 | ||
| Beneficial and ominous aspects of the pleiotropic action of erythropoietin | Q35868143 | ||
| Our ancestral physiological phenotype: an adaptation for hypoxia tolerance and for endurance performance? | Q35895956 | ||
| Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. | Q35954913 | ||
| Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways | Q35997721 | ||
| Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders | Q36050619 | ||
| Effects of erythropoietin on brain function | Q36052901 | ||
| Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications | Q36105780 | ||
| Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia | Q36115014 | ||
| Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism | Q36174439 | ||
| Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins | Q36188312 | ||
| The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems | Q36335414 | ||
| Human erythroid burst-forming unit: T-cell requirement for proliferation in vitro | Q36340694 | ||
| Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients | Q36353302 | ||
| Erythropoietin biology in cancer. | Q36374675 | ||
| Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committ | Q36389445 | ||
| P433 | issue | 3 | |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 183-205 | |
| P577 | publication date | 2007-01-23 | |
| P1433 | published in | European Journal of Haematology | Q15765799 |
| P1476 | title | Erythropoietin after a century of research: younger than ever | |
| P478 | volume | 78 |
| Q59138064 | A Randomized Controlled Trial: Regenerative Effects, Efficacy and Safety of Erythropoietin in Burn and Scalding Injuries |
| Q51148340 | A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. |
| Q44492451 | A mouse model of adult-onset anaemia due to erythropoietin deficiency. |
| Q36843227 | A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial |
| Q33557851 | A novel functional variant in the stem cell growth factor promoter protects against severe malarial anemia |
| Q84514246 | Acute short-term hyperoxia followed by mild hypoxia does not increase EPO production: resolving the "normobaric oxygen paradox" |
| Q41820057 | An extra high dose of erythropoietin fails to support the proliferation of erythropoietin dependent cell lines |
| Q35836904 | Anaemia in kidney disease: harnessing hypoxia responses for therapy |
| Q37258782 | Anemia and the potential role of erythropoiesis-stimulating agents in heart failure |
| Q34017043 | Anemia upregulates lipocalin 2 in the liver and serum. |
| Q51540635 | Anti-Inflammatory Effect of Erythropoietin in the TNBS-induced Colitis. |
| Q37130139 | Approaches to the treatment of anaemia in patients with chronic heart failure |
| Q37999380 | Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments |
| Q33649999 | Blood cells RNA biomarkers as a first long-term detection strategy for EPO abuse in horseracing. |
| Q36733103 | CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia |
| Q42722918 | Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models |
| Q54428734 | Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6. |
| Q42485540 | Cobalt uptake and binding in human red blood cells |
| Q50558097 | Confirmatory Analysis of Continuous Erythropoietin Receptor Activator and Erythropoietin Analogues in Equine Plasma by LC−MS for Doping Control |
| Q37212727 | Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range |
| Q36999068 | Control of erythropoietin gene expression and its use in medicine |
| Q96302126 | Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19? |
| Q39701797 | Covering a broad dynamic range: information processing at the erythropoietin receptor |
| Q37989124 | Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport |
| Q26777810 | Diverse of Erythropoiesis Responding to Hypoxia and Low Environmental Temperature in Vertebrates |
| Q98895939 | Dual Switch Mechanism of Erythropoietin as an Antiapoptotic and Pro-Angiogenic Determinant in the Retina |
| Q36677326 | EPO receptor circuits for primary erythroblast survival |
| Q42003728 | EV-3, an endogenous human erythropoietin isoform with distinct functional relevance |
| Q56974507 | Effects of Erythropoietin on Frataxin Levels and Mitochondrial Function in Friedreich Ataxia – a Dose–Response Trial |
| Q48365906 | Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats |
| Q37784333 | Effects of recombinant human erythropoietin in normal humans |
| Q27010635 | Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials |
| Q48092428 | Endogenous brain erythropoietin is a potent sex-specific respiratory stimulant in adult and newborn mice |
| Q36800398 | Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis |
| Q33791317 | Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia |
| Q36928937 | Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation |
| Q33829114 | Erythrocytosis associated with a novel missense mutation in the HIF2A gene |
| Q24309788 | Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline |
| Q34127573 | Erythropoiesis and Iron Sulfur Cluster Biogenesis |
| Q35176135 | Erythropoietin (EPO) in acute kidney injury |
| Q47360067 | Erythropoietin Attenuates the Brain Edema Response after Experimental Traumatic Brain Injury |
| Q50606157 | Erythropoietin activates nitric oxide synthase in murine erythrocytes. |
| Q41855459 | Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models |
| Q34063671 | Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages |
| Q39005050 | Erythropoietin and co.: intrinsic structure and functional disorder |
| Q48312143 | Erythropoietin as Additive of HTK Preservation Solution in Cold Ischemia/Reperfusion Injury of Steatotic Livers |
| Q92877211 | Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases |
| Q34544348 | Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways |
| Q34017654 | Erythropoietin levels are not independently associated with malaria-attributable severe disease in Mozambican children |
| Q83917078 | Erythropoietin levels in endocrinopathies |
| Q42532323 | Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone |
| Q37968179 | Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy |
| Q45267182 | Erythropoietin production in neuroepithelial and neural crest cells during primitive erythropoiesis |
| Q40457957 | Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease. |
| Q39250670 | Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells |
| Q42928249 | Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model |
| Q41822845 | Erythropoietin use and abuse |
| Q34502176 | Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2 |
| Q42922791 | Erythropoietin: a multimodal neuroprotective agent |
| Q42972651 | Erythropoietin: when liability becomes asset in neurovascular repair |
| Q34182011 | Evaluation of functional erythropoietin receptor status in skeletal muscle in vivo: acute and prolonged studies in healthy human subjects |
| Q33862002 | Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. |
| Q55252265 | Generation of transgenic chickens expressing the human erythropoietin (hEPO) gene in an oviduct-specific manner: Production of transgenic chicken eggs containing human erythropoietin in egg whites. |
| Q34203463 | Glucose, insulin, and oxygen interplay in placental hypervascularisation in diabetes mellitus. |
| Q33926530 | HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism |
| Q35138319 | Hematological parameters, and hematopoietic growth factors: EPO and IL-3 in response to whole-body cryostimulation (WBC) in military academy students |
| Q38262836 | High-dose erythropoietin for tissue protection |
| Q38882599 | Hypometabolism as the ultimate defence in stress response: how the comparative approach helps understanding of medically relevant questions |
| Q42147890 | Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis |
| Q24609166 | Hypoxic regulation of erythropoiesis and iron metabolism |
| Q50454067 | Impaired expression of HIF-2α induces compensatory expression of HIF-1α for the recovery from anemia. |
| Q33389236 | Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care? |
| Q47634204 | Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings. |
| Q40825620 | Integrity of the prolyl hydroxylase domain protein 2:erythropoietin pathway in aging mice |
| Q37818329 | Intranasal erythropoietin therapy in nervous system disorders |
| Q27317145 | Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice |
| Q28075747 | Lung Structure and the Intrinsic Challenges of Gas Exchange |
| Q35064235 | MCPIP1 deficiency in mice results in severe anemia related to autoimmune mechanisms |
| Q47109963 | NCOR1 modulates erythroid disorders caused by mutations of thyroid hormone receptor α1. |
| Q50042158 | Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke |
| Q37510763 | Neuroprotective role of erythropoietin by antiapoptosis in the retina. |
| Q38896197 | Nickel in equine sports drug testing - pilot study results on urinary nickel concentrations |
| Q37254556 | Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. |
| Q38791521 | Novel bioluminescent binding assays for interaction studies of protein/peptide hormones with their receptors |
| Q36845732 | Novel opportunities for computational biology and sociology in drug discovery |
| Q37385426 | Novel opportunities for computational biology and sociology in drug discovery. |
| Q33620938 | Nucleated red blood cells are a direct response to mediators of inflammation in newborns with early-onset neonatal sepsis. |
| Q37946499 | Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials |
| Q38848944 | Probing protease sensitivity of recombinant human erythropoietin reveals α3-α4 inter-helical loop as a stability determinant. |
| Q24633871 | Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii |
| Q48040213 | Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes |
| Q37390664 | Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients |
| Q41173431 | Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis |
| Q35356050 | Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution |
| Q43099001 | Regulation of Bone Marrow Angiogenesis by Osteoblasts during Bone Development and Homeostasis |
| Q37063716 | Regulation of erythropoiesis by hypoxia-inducible factors |
| Q56169800 | Regulation of erythropoietin production |
| Q42271017 | Renal Anemia Model Mouse Established by Transgenic Rescue with an Erythropoietin Gene Lacking Kidney-Specific Regulatory Elements |
| Q42564390 | Reno-endocrinal disorders: A basic understanding of the molecular genetics |
| Q41494887 | Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies |
| Q89081807 | Robust increases in erythropoietin production by the hypoxic fetus is a response to protect the brain and other vital organs |
| Q38603246 | Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis |
| Q43898191 | Skeletal muscle intrinsic functional properties are preserved in a model of erythropoietin deficient mice exposed to hypoxia. |
| Q47375569 | Skeletal muscle involvement in friedreich ataxia and potential effects of recombinant human erythropoietin administration on muscle regeneration and neovascularization |
| Q35192634 | Specific contribution of the erythropoietin gene 3' enhancer to hepatic erythropoiesis after late embryonic stages |
| Q34411804 | Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities. |
| Q39733951 | Subtle distinct regulations of late erythroid molecular events by PI3K/AKT-mediated activation of Spi-1/PU.1 oncogene autoregulation loop |
| Q37333335 | Suppression of a novel hematopoietic mediator in children with severe malarial anemia |
| Q37100284 | Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin. |
| Q36677186 | Synergistic upregulation of erythropoietin receptor (EPO-R) expression by sense and antisense EPO-R transcripts in the canine lung |
| Q40757172 | Systemic endogenous erythropoietin and associated disorders in extremely preterm newborns |
| Q28584214 | Targeting the erythropoietin receptor on glioma cells reduces tumour growth |
| Q43268796 | Tetracycline-dependent expression of the human erythropoietin gene in transgenic chickens |
| Q37799606 | The HIF Pathway and Erythrocytosis |
| Q60051012 | The Levels of Hepcidin and Erythropoietin in Pregnant Women with Anemia of Various Geneses |
| Q37995093 | The nonhematopoietic effects of erythropoietin in skin regeneration and repair: from basic research to clinical use. |
| Q26864149 | The pleiotropic effects of erythropoietin in infection and inflammation |
| Q43275567 | The protective effect of erythropoietin on the acute phase of corrosive esophageal burns in a rat model |
| Q38123160 | The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how much do we really know? |
| Q34227757 | The use of genes for performance enhancement: doping or therapy? |
| Q39291945 | Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. |
| Q39343029 | Topological transformation of liposomes by a membrane-affecting domain of recombinant human erythropoietin |
| Q36102876 | Two new mutations in the HIF2A gene associated with erythrocytosis. |
| Q39836420 | Use of Erythropoietin as adjuvant therapy in nerve reconstruction |
| Q58121715 | Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin? |
| Q44653851 | Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: a randomized placebo controlled trial |
| Q36758037 | Widespread expression of erythropoietin receptor in brain and its induction by injury |
Search more.